Jacobs Levy Equity Management, Inc Tango Therapeutics, Inc. Transaction History

Jacobs Levy Equity Management, Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$7.51 - $12.88 $258,914 - $444,050	-34,476 Reduced 61.77%	21,338 $169,000
Q4 2023 Feb 14, 2024	SELL	$6.52 - $12.01 $571,588 - $1.05 Million	-87,667 Reduced 61.1%	55,814 $552,000
Q3 2023 Nov 16, 2023	SELL	$2.93 - $11.26 $513,614 - $1.97 Million	-175,295 Reduced 54.99%	143,481 $1.62 Million
Q2 2023 Aug 14, 2023	SELL	$2.67 - $4.7 $231,726 - $407,908	-86,789 Reduced 21.4%	318,776 $1.06 Million
Q1 2023 May 15, 2023	BUY	$3.76 - $8.06 $222,193 - $476,297	59,094 Added 17.06%	405,565 $1.6 Million
Q4 2022 Feb 14, 2023	BUY	$3.41 - $8.29 $1,868 - $4,542	548 Added 0.16%	346,471 $2.51 Million
Q3 2022 Nov 15, 2022	BUY	$3.25 - $5.46 $1.12 Million - $1.89 Million	345,923 New	345,923 $1.25 Million

123

91.7M

3.1K

1.5K

Ticker TNGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 88,067,296
Market Cap $359M
Description
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.